<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="drugdevelopR">
<title>Time-to-event Outcome Variables • drugdevelopR</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Time-to-event Outcome Variables">
<meta property="og:description" content="drugdevelopR">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="active nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Bias_adjustment.html">Methods for Discounting of Phase II Results - Bias Adjustment</a>
    <a class="dropdown-item" href="../articles/Binary_distributed_outcomes.html">Binary Distributed Outcome Variables</a>
    <a class="dropdown-item" href="../articles/Fixed_and_prior_distributions.html">Fixed effects and prior distributions</a>
    <a class="dropdown-item" href="../articles/Interpreting_Output.html">Interpreting the Rest of the Output</a>
    <a class="dropdown-item" href="../articles/More_Parameters.html">More Parameters to Adapt to Specific Settings and Individual Needs</a>
    <a class="dropdown-item" href="../articles/Multiarm_Trials.html">Multiarm - Methods for Multi-Arm Programs</a>
    <a class="dropdown-item" href="../articles/Multiple_Endpoints.html">Multiple_Endpoints</a>
    <a class="dropdown-item" href="../articles/Multitrial.html">Multitrial Programs - Methods for Programs with Several Phase III Trials</a>
    <a class="dropdown-item" href="../articles/Time-to-event_outcomes.html">Time-to-event Outcome Variables</a>
    <a class="dropdown-item" href="../articles/introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav">
<li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>

    
  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Time-to-event Outcome Variables</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/vignettes/Time-to-event_outcomes.Rmd" class="external-link"><code>vignettes/Time-to-event_outcomes.Rmd</code></a></small>
      <div class="d-none name"><code>Time-to-event_outcomes.Rmd</code></div>
    </div>

    
    
<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>. In the
introduction, the observed outcome variable “tumor growth” was normally
distributed. However, the drugdevelopR package is not only restricted to
normally distributed outcome variables but also binary distributed
outcome variables and a time-to-event outcome variables. In this article
we want explain how the setting with time-to-event variables works.</p>
<div class="section level2">
<h2 id="the-example-setting">The example setting<a class="anchor" aria-label="anchor" href="#the-example-setting"></a>
</h2>
<p>Suppose we are developing a new tumor treatment, <em>exper</em>. The
patient variable that we want to investigate is how long the patient
survives without further progression of the tumor (progression free
survival). This is a time to event outcome variable.</p>
<p>Within our drug development program, we will compare our experimental
treatment <em>exper</em> to the control treatment <em>contro</em>. The
treatment effect measure is given by <span class="math inline">\(\theta
= −\log(HR)\)</span>, which is the negative logarithm of the hazard
ratio <span class="math inline">\(HR\)</span>, which is the ratio of the
hazard rates. If we assume that unfavorable events as tumor progression
occur only 75% as often as in the control group, we have a hazard ratio
of 0.75.</p>
</div>
<div class="section level2">
<h2 id="applying-the-package-to-the-example">Applying the package to the example<a class="anchor" aria-label="anchor" href="#applying-the-package-to-the-example"></a>
</h2>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/Sterniii3/drugdevelopR" class="external-link">drugdevelopR</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; Loading required package: mvtnorm</span></span>
<span><span class="co">#&gt; Loading required package: doParallel</span></span>
<span><span class="co">#&gt; Loading required package: foreach</span></span>
<span><span class="co">#&gt; Loading required package: iterators</span></span>
<span><span class="co">#&gt; Loading required package: parallel</span></span>
<span><span class="co">#&gt; Loading required package: msm</span></span>
<span><span class="co">#&gt; Loading required package: cubature</span></span></code></pre></div>
<div class="section level3">
<h3 id="defining-all-necessary-parameters">Defining all necessary parameters<a class="anchor" aria-label="anchor" href="#defining-all-necessary-parameters"></a>
</h3>
<p>In order to apply the package to the setting from our example, we
need to specify the following parameters:</p>
<ul>
<li>
<code>hr1</code> is our hazard ratio. As already explained above, we
assume that our experimental treatment <em>exper</em> leads to
unfavorable events occurring only 75% of times compared to the control
treatment <em>contro</em>. Therefore, we set <code>hr1 = 0.75</code>.
For now, we will assume that the probabilities are fixed and independent
of any prior distribution. Thus, we will set
<code>fixed = TRUE</code>.</li>
<li>
<code>d2min</code> and <code>d2max</code> specify the minimal and
maximal number of events for the phase II trial. The package will search
for the optimal sample size within this region. For now, we want the
program to search for the optimal sample size in the interval between 20
and 400 events. In addition, we will tell the program to search this
region in steps of four participants at a time by setting
<code>stepd2 = 4</code>.</li>
<li>
<code>hrgomin</code> and <code>hrgomax</code> specify the minimal
and maximal threshold value for the go/no-go decision rule in terms of
the negative logarithm of the hazard ratio. The package will search for
the optimal threshold value within this region. For now, we want the
program to search in the interval between 0.7 and 0.9 while going in
steps of <code>stephrgo = 0.01</code>. Note, that he lower bound of the
decision rule set for represents the smallest size of treatment effect
observed in phase II allowing to go to phase III, so it can be used to
model the minimally clinically relevant effect size. Moreover, note that
the interval specified above corresponds to the set <span class="math inline">\(\{-\log(0.9), ..., -\log(0.7)\}\)</span>.</li>
<li>
<code>xi2</code> and <code>xi3</code> correspond to the event rates
in phase II and phase III. After calculating the optimal number of
events <code>d2</code> and <code>d3</code>, the event rates are used to
calculate the optimal sample sizes in phase II and III. We assume event
rates of 0.7 in each phase, indicating that 70 events correspond to an
optimal sample size of 100, respectively.</li>
<li>
<code>c02</code> and <code>c03</code> are fixed costs for phase II
and phase III respectively. We will set the phase II costs to 100 and
the phase III costs to 150 (in <span class="math inline">\(10^5\)</span>$), i.e we have fixed costs of 10 000
000$ in phase II and 15 000 000$ in phase III. Note that the currency of
the input values does not matter, so an input value for <code>c02</code>
of 15 could also be interpreted as fixed costs of 1 500 000€ if
necessary.</li>
<li>
<code>c2</code> and <code>c3</code> are the costs in phase II and
phase III per patient. We will set them to be 0.75 in phase II and 0.1
in phase III. Again, these values are given in <span class="math inline">\(10^5\)</span>$, i.e we have per patient costs of
75 000$ in phase II and 100 000$ in phase III.</li>
<li>
<code>b1</code>, <code>b2</code> and <code>b3</code> are the
expected small, medium and large benefit categories for successfully
launching the treatment on the market for each effect size category in
<span class="math inline">\(10^5\)</span>$. We will define a small
benefit of 1000, a medium benefit of 2000, and a large benefit of 3000.
The effect size categories directly correspond to the treatment effect,
i.e. if the the treatment effect is between 1 and 0.95 (in terms of the
risk ratio) we have a small treatment effect, hence yielding expected
benefits of the drug development program of 100 000 000$.</li>
<li>
<code>alpha</code> is the specified significance level. We will set
<code>alpha = 0.05</code>.</li>
<li>1 - <code>beta</code> is the minimal power that we require for our
drug development program. We will set <code>beta = 0.1</code>, meaning
that we require a power of 90%.</li>
</ul>
<p>As in the setting with normally distributed outcomes, the treatment
effect may be fixed (as in this example) or follows a prior distribution
(see <a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html">Fixed
or Prior</a>). Note, that in the case of using a prior distribution, the
following input parameters have to be specified, which differ from the
setting with normally distributed outcomes: * Instead of the parameters
<code>in1</code> and <code>in2</code> for the “amount of information”,
we have to use the parameters <code>id1</code> and <code>id2</code>
which represent the “number of events”. They refer to the number of
events which were observed in the study to determine the treatment
effect. If in our study 210 events could be observed, then the value for
<code>id1</code> is set to be 420. If we assume assume that in the study
of the other research group 420 events could be observed, the parameter
value for <code>id2</code> is 420. * Moreover, we do not need truncation
values, i.e. values for the parameters <code>a</code> and
<code>b</code>.</p>
<p>Furthermore, all options to adapt the program to your specific needs
are also available in this setting (see <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">More
Paramters</a>).</p>
<p>Now that we have defined all parameters needed for our example, we
are ready to feed them to the package. We will use the function
<code><a href="../reference/optimal_tte.html">optimal_tte()</a></code>, which calculates the optimal sample size and
the optimal threshold value for a time-to-event outcome variable.</p>
<div class="sourceCode" id="cb2"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/optimal_tte.html">optimal_tte</a></span><span class="op">(</span>w <span class="op">=</span> <span class="fl">0.3</span>,                               <span class="co"># define parameters for prior</span></span>
<span>   hr1 <span class="op">=</span> <span class="fl">0.75</span>, hr2 <span class="op">=</span> <span class="fl">0.8</span>, id1 <span class="op">=</span> <span class="fl">210</span>, id2 <span class="op">=</span> <span class="fl">420</span>,           <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span>
<span>   d2min <span class="op">=</span> <span class="fl">20</span>, d2max <span class="op">=</span> <span class="fl">400</span>, stepd2 <span class="op">=</span> <span class="fl">5</span>,                   <span class="co"># define optimization set for d2</span></span>
<span>   hrgomin <span class="op">=</span> <span class="fl">0.7</span>, hrgomax <span class="op">=</span> <span class="fl">0.9</span>, stephrgo <span class="op">=</span> <span class="fl">0.01</span>,         <span class="co"># define optimization set for HRgo</span></span>
<span>   alpha <span class="op">=</span> <span class="fl">0.05</span>, beta <span class="op">=</span> <span class="fl">0.1</span>, xi2 <span class="op">=</span> <span class="fl">0.7</span>, xi3 <span class="op">=</span> <span class="fl">0.7</span>,        <span class="co"># drug development planning parameters</span></span>
<span>   c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,               <span class="co"># define fixed and variable costs</span></span>
<span>   K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                            <span class="co"># set constraints</span></span>
<span>   steps1 <span class="op">=</span> <span class="fl">1</span>,  stepm1 <span class="op">=</span> <span class="fl">0.95</span>, stepl1 <span class="op">=</span> <span class="fl">0.85</span>,             <span class="co"># define boundary for  effect size categories</span></span>
<span>   b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                       <span class="co"># define expected benefits</span></span>
<span>   gamma <span class="op">=</span> <span class="fl">0</span>,                                             <span class="co"># assume different/same population structures </span></span>
<span>   fixed <span class="op">=</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if  effects are fixed or random</span></span>
<span>   skipII <span class="op">=</span> <span class="cn">FALSE</span>,                                        <span class="co"># more parameters</span></span>
<span>   num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span></span></code></pre></div>
</div>
<div class="section level3">
<h3 id="interpreting-the-output">Interpreting the output<a class="anchor" aria-label="anchor" href="#interpreting-the-output"></a>
</h3>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span></span>
<span><span class="co">#&gt;        u HRgo  d2  d3   d  n2  n3   n  pgo sProg   hr   K   N    S  K2  K3</span></span>
<span><span class="co">#&gt; 1 584.57 0.88 210 441 651 300 630 930 0.88  0.71 0.75 Inf Inf -Inf 325 761</span></span>
<span><span class="co">#&gt;   sProg1 sProg2 sProg3 steps1 stepm1 stepl1 alpha beta xi2 xi3 c02 c03   c2 c3</span></span>
<span><span class="co">#&gt; 1   0.09    0.3   0.33      1   0.95   0.85  0.05  0.1 0.7 0.7 100 150 0.75  1</span></span>
<span><span class="co">#&gt;     b1   b2   b3 gamma</span></span>
<span><span class="co">#&gt; 1 1000 2000 3000     0</span></span></code></pre></div>
<p>The program returns a total of sixteen output values and the input
paramters. For now, we will only look at the most important ones:</p>
<ul>
<li>
<code>res$d2</code> is the optimal number of events for phase II and
<code>res$d3</code> the resulting number of events for phase III. We see
that the optimal scenario requires 210 events in phase II and 441 events
in phase III, which correspond to 300 participants in phase II and 630
in phase III.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.88 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
584.57, i.e we have an expected utility of 58 457 000$.</li>
</ul>
</div>
</div>
<div class="section level2">
<h2 id="where-to-go-from-here">Where to go from here<a class="anchor" aria-label="anchor" href="#where-to-go-from-here"></a>
</h2>
<p>In this article we introduced the setting, when the outcome is a
time-to-event variable. For more information on how to use the package,
see:</p>
<ul>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic
example.</li>
<li>
<em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Binary_distributed_outcomes.html">binary
endpoints</a>.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li>
<em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html">multiple
phase III trials</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html">multi-arm
trials</a>, or multiple endpoints.</li>
<li>
<em>Parallel computing:</em> Be faster at calculating the optimum by
using parallel computing.</li>
</ul>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by Stella Preussler.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
